Yaral Pharma is led
by a seasoned team of executives with extensive experience in the generics
industry. It will start commercializing its first product from IBSA's corporate
pipeline in January 2023. Its current product portfolio includes multiple
therapeutic areas, such as pain and endocrinology. The company plans to expand
its operations through external partnerships and opportunities.
IBSA is a global
company that has a long history of delivering high-quality products and
reliable supply chains. It is focused on developing and manufacturing a wide
range of generics and brands, which it markets across multiple therapeutic
areas. Its innovative delivery systems, such as patch technology and soft gel
capsules, are also used to treat various conditions.
IBSA is widely
recognized for its achievements in the field of reproductive medicine. It is
also one of the world's leading producers of hyaluronic acid-based products.
Stephen Beckman,
the CEO of Yaral Pharma, noted that the company's parent company, IBSA, is
known for its innovative products and technologies that improve people's health
and wellness. He said that the company would draw on its many strengths to
provide its customers with high-quality generics and exceptional service.
About Authorized Generics
The FDA defines an
authorized generic as a drug that is marketed without the label of its brand
name. In other words, it is the same as the branded product in terms of its
active and inactive ingredients and manufacturing process. This type of drug is
typically cheaper than the branded product.
About Yaral Pharma
The US generics
subsidiary of IBSA, Yaral Pharma Inc., is focused on providing high-quality,
affordable, and complex generic medicines to improve the healthcare outcomes of
patients. It is proud to carry on the same tradition of innovation and
excellence as its parent company.
Yaral Pharma is
dedicated to providing its customers with high-quality and affordable generics
and complex generic medicines. It is committed to ensuring that they have
access to the latest technology and supplies, and it is able to deliver
exceptional service. For more information about the company, please visit its
website at www.yaral-pharma.com or contact 866-218-9009.
About IBSA
Founded in 1945,
IBSA is a multinational pharmaceutical company that is based in Switzerland.
Its products are currently available in over 90 countries across five
continents. The company has a total turnover of 800 million Swiss francs, and
it employs over 2,000 people at its various facilities.
IBSA has a vast
portfolio of approved patents and various development programs. It has a wide
range of products that are focused on different therapeutic areas, such as pain
and inflammation, reproductive medicine, dermatology, and uro-gynaecology.
No comments:
Post a Comment